Compare · FEMY vs SYK
FEMY vs SYK
Side-by-side comparison of Femasys Inc. (FEMY) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FEMY and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $126.81B, about 5312.6x FEMY ($23.9M).
- FEMY has been more active in the news (18 items in the past 4 weeks vs 9 for SYK).
- SYK has more recent analyst coverage (25 ratings vs 3 for FEMY).
- Company
- Femasys Inc.
- Stryker Corporation
- Price
- -
- -
- Market cap
- $23.9M
- $126.81B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 18
- 9
- Recent ratings
- 3
- 25
Femasys Inc.
Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest FEMY
- SEC Form D filed by Femasys Inc.
- Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®
- SEC Form 10-Q filed by Femasys Inc.
- Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update
- Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents
- SEC Form 4 filed by Director Eichenbaum Kenneth D.
- SEC Form 4 filed by Director Uzialko Edward R
- SEC Form 4 filed by Director Milnes Alistair
- SEC Form 4 filed by Director Larsen Charles
- Chief Clinical-Medical Affairs Mifek Jeffrey Gerald bought $10,000 worth of shares (3,125 units at $3.20) (SEC Form 4)
Latest SYK
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)
- Officer King Debra covered exercise/tax liability with 533 shares, decreasing direct ownership by 7% to 7,036 units (SEC Form 4)
- VP, Chief Legal Officer Fletcher Robert S covered exercise/tax liability with 94 shares, decreasing direct ownership by 0.89% to 10,488 units (SEC Form 4)
- VP, Chief HR Officer Fink M Kathryn covered exercise/tax liability with 111 shares, decreasing direct ownership by 0.84% to 13,027 units (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation